The Trial Is Done. Now Comes the Fight to Actually Get This Drug to People.

We already reported the Phase 3 headline numbers. Average 28.3% body weight loss at the 12mg dose. Seventy pounds gone in 80 weeks. Forty-five percent of participants hitting the bariatric surgery threshold. You know the results.

Eli Lilly says it plans to launch retatrutide next year, according to Kenneth Custer, the company's president of cardiometabolic health, speaking to Reuters. That means an FDA submission is imminent — or already in motion.

That's the clock that matters now.

The Competition Just Got Humiliated — Including Lilly's Own Drug

Retatrutide's lowest test dose — 4mg — produced 19% average body weight loss, according to Time magazine's reporting on Eli Lilly's press release. That's roughly equivalent to the highest dose of Zepbound, Lilly's currently approved drug.

Zepbound and Novo Nordisk's Wegovy — the two market leaders — top out at 15% to 20% weight loss, according to The Guardian. Retatrutide's middle dose, 9mg, hit 25.9%. Its top dose hit 28.3%.

The worst version of the new drug performs as well as the best version of the current best drugs. Novo Nordisk shares dropped 0.7% on the news, per Reuters. The market understood the implications immediately.

The Side Effect Question Isn't Going Away

Earlier trial phases flagged dysesthesia — an abnormal, sometimes painful skin sensation — as a side effect specific to retatrutide that doesn't show up with other GLP-1 drugs. It's a novel neurological side effect with no parallel in the existing drug class.

The latest Phase 3 data showed fewer patients reporting dysesthesia than earlier trials suggested, per Reuters. Analysts flagged the improvement. But Reuters did NOT report that dysesthesia disappeared entirely from the data — just that it was less frequent.

About 11% of participants on the highest dose dropped out due to side effects, according to Time. Gastrointestinal issues — nausea, vomiting, diarrhea — remain standard across the entire GLP-1 drug class. Real-world dropout rates for existing drugs run closer to 15%, per Time's reporting.

One in nine people stopping the drug at the highest dose is a significant rate, even if it falls short of alarming.

What Nobody Is Pricing Out

Every major outlet covering this story — Time, The Guardian, Reuters via CP24, and Reason — leads with the weight loss numbers. NOT ONE of them mentions what retatrutide will cost.

Zepbound currently runs approximately $550 per month with manufacturer coupons for commercially insured patients, and significantly more without. Wegovy lists around $1,350 per month before insurance.

If retatrutide performs dramatically better than both, expect Lilly to price it accordingly. The people who need this drug most — lower-income Americans with severe obesity — are the least likely to have insurance that covers it.

The drug could be a medical revolution that 40 million Americans can't afford.

RFK Jr.'s Awkward Position Gets More Awkward

Reason's Ronald Bailey flagged something the others buried: HHS Secretary Robert F. Kennedy Jr. initially attacked GLP-1 drugs as proof that Americans are "so stupid and so addicted to drugs" — his words. Then President Trump endorsed the drugs publicly, and Kennedy reversed course.

Now the most powerful weight loss drug ever tested is about to go through the FDA that Kennedy's department oversees. His agency will review the dysesthesia data. His agency will set the approval timeline.

The man who called these drugs a symptom of American stupidity is now the gatekeeper for the drug that might end the obesity epidemic.

The 65% Number That Deserves More Attention

The Guardian reported one statistic that hasn't gotten enough play: 65.3% of participants on the 12mg dose reduced their BMI below 30 — the clinical cutoff for obesity. That includes 37.5% of people who started the trial with a BMI of 40 or above, meaning severely obese patients.

This represents the medical reclassification of millions of people out of the "obese" category entirely. The downstream effects on diabetes rates, cardiovascular disease, cancer risk, and healthcare costs are enormous — and largely uncalculated in current coverage.

Dr. Susan Spratt, endocrinologist and senior medical director at Duke Health, told NBC News: "This is the largest weight loss I've ever seen in any medication trial."

What Comes Next

The FDA approval process typically runs 6 to 12 months after a complete submission. If Lilly files in mid-2026, a 2027 approval is realistic — not a 2026 launch, despite Custer's optimism. Regulatory timelines rarely accelerate based on corporate announcements.

What regular people need to watch: Will insurance cover it? Will Medicare negotiate the price? Will Kennedy's FDA move at normal speed or drag its feet?